Opendata, web and dolomites


Accellta Market Study

Total Cost €


EC-Contrib. €






 Accellta project word cloud

Explore the words cloud of the Accellta project. It provides you a very rough idea of what is the project "Accellta" about.

differentiated    stem    meeting    hold    customers    infrastructure    therapies    affordable    protected    offers    drug    provider    centre    personalised    premium    plan    industry    sme    promise    emerge    huge    proper    innovative    services    regenerative    screening    acknowledged    mass    hpsc    utmost    ip    1998    lines    advancing    pharmaceutical    newly    remarkably    accellta    consultation    intellectual    ltd    pioneering    3d    professionally    reagents    quantities    technologies    culturing    organizing    techniques    manner    israel    succeeded    property    medicine    leader    technion    granted    expertise    2012    companies    vision    direction    cardiomyocytes    market    dated    hpscs    pluripotent    grade    human    discoveries    national    animal    company    neuronal    license    suspension    despite    solutions    cell    cells    databases    establishment    team    clinical    industrial    quality    biomedical    directives    exceptional    patents    demands    free   

Project "Accellta" data sheet

The following table provides information about the project.


Organization address
address: MALAT BUILDING - 3rd floor - TECHNION CITY
city: HAIFA
postcode: 3200004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACCELLTA LTD IL (HAIFA) coordinator 50˙000.00


 Project objective

Human pluripotent stem cells (hPSCs) and hPSCs-derived differentiated cells, such as cardiomyocytes and neuronal cells, are rapidly advancing discoveries in drug screening and development processes and hold much promise for personalised regenerative medicine. The affordable mass production of industrial-grade high quality hPSCs will enable meeting the research and clinical demands of the rapidly growing stem cell market. Accellta Ltd. offers a range of innovative solutions for culturing mass quantities of premium quality stem cells in a cost-effective manner. These solutions are the result of research dated since 1998 at the Stem Cell Centre at the Technion – Israel Institute of Technology. As a newly developed SME, this company has exceptional expertise in innovative hPSC culturing solutions, including growing stem cells in 3D suspension, with unique, animal-free reagents. These technologies are protected by numerous pioneering, granted and acknowledged patents and since its establishment in 2012. This SME already succeeded to license its IP to multi-national cell research companies. Accellta's future vision is to become a leading provider of premium quality differentiated cell lines and services to customers, which include pharmaceutical and biomedical companies. Despite the huge market potential, proper industry and market research plan is essential and organizing a professionally conducted study, using proper consultation and market research databases, is of the utmost importance. Understanding the market's direction and demands would provide the directives in which the company can proceed and find success. Accellta has the know-how, intellectual property, team and infrastructure required to emerge as a leader in this field. The company's remarkably unique techniques in pluripotent stem cell culturing would provide high quality hPSCs-derived differentiated cells will advance drug development and regenerative therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACCELLTA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACCELLTA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More